OttoOrleanYangMD

Professor, Medicine, UCLA School of Medicine

Dr. Yang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
200 Medical Plaza
# 365C
Los Angeles, CA 90095
Phone+1 310-206-7663

Fax+1 310-206-1609

Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1993 - 1997
NYU Grossman School of MedicineResidency, Internal Medicine, 1990 - 1993
The Warren Alpert Medical School of Brown UniversityClass of 1990

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

PubMed

A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19.
Harish Seethamraju, Otto O Yang, Richard Loftus, Onyema Ogbuagu, Daniel Sammartino
Clinical Therapeutics. 2024-11-01
Update on Managing the Risks of Exposure to Lentiviral and Retroviral Vectors.
Gary R Fujimoto, Dawn P Wooley, Karen B Byers, Otto O Yang, Amy J Behrman
Journal of Occupational and Environmental Medicine. 2024-10-01
2 citations
SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir.
Kanal Singh, Kevin Rubenstein, Viviane Callier, Katy Shaw-Saliba, Adam Rupert
The Journal of Infectious Diseases. 2024-09-23

Journal Articles

Cross-Reactivity Against Multiple HIV-1 Epitopes Is Characteristic of HIV-1-Specific Cytotoxic T Lymphocyte Clones
Otto Yang, MD, mBio
Highly Attenuated Infection with a Vpr-Deleted Molecular Clone of HIV-1
Peter A Anton, Jennifer A Fulcher, Otto O Yang, Joel N Blankson, The Journal of Infectious Diseases

Vaccines and Long COVID: What Do We Know?October 4th, 2024
Here’s What to Know About the COVID-19 Summer SurgeAugust 30th, 2024
Right Here's What to Know Concerning the COVID-19 Summer Time SurgeAugust 30th, 2024
Join now to see all

Translational AIDS And Viral Pathogenesis Training (51)National Institute Of Allergy And Infectious Diseases2010–2012
HIV-1 Escape From Inhibition By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases1999–2012
Identifying And Closing GAPS In TCR Coverage Of HIV-1 EscapeNational Institute Of Allergy And Infectious Diseases2011
Addressing Intra-/Inter-Clade Diversity In HIV Vaccine Design By Immune FocusingNational Institute Of Allergy And Infectious Diseases2010–2011
Immune Pressure On HIV-1 Nef By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases2002–2011
Mucosal And Peripheral NK-T Cells In HIV InfectionNational Institute Of Allergy And Infectious Diseases2006–2007
HIV-1 Excape From Inhibiton By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases2003–2007
HIV-1 Escape From Inhibition By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases1998–1999
Inhibition Of HIV 1 By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases1996–1998
Inhibition Of HIV-1 By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases1995–1996